In addition, reports have indicated that STAT3 and STAT5 contribute to the resistance of CML cells to tyrosine kinase inhibitors (TKI).28, 29. This evidence concerns the gene STAT5B and chronic myelogenous leukemia, BCR-ABL1 positive.